在日本使用15肺炎球菌合疫苗对儿科免疫计划的成本效益分析
Atsushi Tajima1, Machiko Abe1, Jessica Weaver2
1MSD K.K., Outcomes Research, Market Access, Tokyo, Japan.
在日本,用于小儿疫苗接种的15价值肺炎球菌合疫苗 (V114) 比13价值PCV (PCV13) 更具成本效益. V114提供了更大的健康益处和显著的成本节省,证明了它的价值.
科学领域:
- 卫生经济学 卫生经济学
- 疫苗学 疫苗学 疫苗学
- 公共卫生 公共卫生
背景情况:
- 15性肺炎球菌合疫苗 (PCV15或V114) 刚刚在日本获得批准用于儿科.
- 肺炎球菌病 (PDs) 构成了严重的公共卫生问题,需要有效的疫苗接种策略.
研究的目的:
- 为了评估V114的成本效益,与13肺炎球菌合疫苗 (PCV13) 相比,用于日本的儿科疫苗接种.
- 从社会和医疗保健支付者的角度评估V114和PCV13之间的经济和健康结果差异.
主要方法:
- 采用决策分析马尔科夫模型,对日本出生队列在10年内模拟成本和健康结果.
- 该模型结合了直接和间接的成本,疫苗的有效性,间接的保护和疫苗的衰退,用于PD,如侵入性PD (IPD),非细菌性肺炎球菌性肺炎 (NBPP) 和急性中耳炎 (AOM).
主要成果:
- V114在PCV13上表现出主导地位,在质量调整后的寿命年中获得了24年的增量收益,并在基准情况下降低了超过3.65亿日元的总成本.
- 预计V114可以预防1832例AOM,1333例NBPP和25例IPD病例.
- 场景和灵敏度分析证实V114在大多数情况下是占主导地位的战略.
结论:
- 与日本的PCV13相比,用V114对儿童进行疫苗接种是一种节省成本和更有利的策略.
- 从社会和医疗保健支付者的角度来看,这些发现是强有力的,支持V114的实施.
更多相关视频
06:22Standardization of Transfer across Labs between Flow Cytometers for Detection of Lymphocytes in Japanese Encephalitis Vaccinated Children
Published on: February 10, 2023
13:47Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
Published on: May 19, 2020
相关概念视频
Vaccinations
Preventive Healthcare Services
Antimicrobial Effectiveness
Dose-Response Relationship: Potency and Efficacy
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
